Onartuzumab ineffective in non-small-cell lung cancer

Results from the phase 3 randomised, placebo-controlled METLung trial of the MET-targeted therapy onartuzumab plus erlotinib versus erlotinib plus placebo in locally advanced or metastatic non-small-cell lung cancer (NSCLC) showed that patients treated with the combination did not do as well as those who were given.